Advice for n-of-1 Drug Developers
The FDA has issued draft recommendations to help developers of antisense oligonucleotide (ASO) therapies for rare, debilitating genetic diseases to conduct human trials with a single participant, known as n-of-1 trials.
Source: JAMA - Category: General Medicine Source Type: research
More News: General Medicine | Genetics